New drug shows promise in preventing transplant complication

NCT ID NCT02867384

Completed Prevention Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times

Summary

This study tested whether the drug obinutuzumab can prevent chronic graft-versus-host disease (cGVHD), a serious complication after a stem cell transplant. 181 people who had a stem cell transplant received obinutuzumab or a placebo. The goal was to see if the drug could reduce the need for steroids to treat cGVHD in the first year after transplant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States
Masonic Cancer Center

Minneapolis, Minnesota, 55455, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Stanford University

Palo Alto, California, 94305, United States

Conditions

Explore the condition pages connected to this study.

GRAFT VS HOST DISEASE